Highline Capital Management’s Ultragenyx Pharmaceutical RARE Stock Holding History

Highline Capital Management’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-295,653	Closed	-$12.6M	–	28
2019 Q3	$12.6M	Sell	295,653 -94,800	-24%	-$5.15M	1.85%	19
2019 Q2	$24.8M	Sell	390,453 -219,610	-36%	-$14M	1.81%	23
2019 Q1	$42.3M	Buy	610,063 +151,550	+33%	+$8.66M	2.66%	18
2018 Q4	$19.9M	Buy	458,513 +30,393	+7%	+$1.66M	1.34%	23
2018 Q3	$32.7M	Buy	428,120 +18,120	+4%	+$1.47M	1.51%	20
2018 Q2	$31.5M	Buy	+410,000	New	+$26.5M	1.06%	30

Other funds holding RARE

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Highline Capital Management's RARE Position: Q4 2019 in Review

Highline Capital Management sold out of Ultragenyx Pharmaceutical (RARE) in Q4 2019, closing a stake of 295,653 shares — an estimated $12.6M sold.

Highline Capital Management first reported a position in RARE in Q2 2018 and held it in 6 quarters. The position peaked at $42.3M in Q1 2019. 172 funds tracked by Wall St. Rank hold RARE as of Q4 2019.

Highline Capital Management reported no remaining Ultragenyx Pharmaceutical position as of Q4 2019 after selling out during the quarter.
Highline Capital Management sold 295,653 Ultragenyx Pharmaceutical shares in Q4 2019, an estimated $12.6M.
Highline Capital Management first reported a position in Ultragenyx Pharmaceutical in Q2 2018 and held it in 6 quarters.
Highline Capital Management's Ultragenyx Pharmaceutical position peaked at $42.3M in Q1 2019.
172 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q4 2019.

Based on Highline Capital Management's 13F filing for Q4 2019, filed 14 Feb 2020.